These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 15799415)

  • 21. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 23. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
    Jacobi AM; Dörner T
    Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocrelizumab: a step forward in the evolution of B-cell therapy.
    Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
    Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
    Edwards JC; Leandro MJ; Cambridge G
    Curr Dir Autoimmun; 2005; 8():175-92. PubMed ID: 15564721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab for rheumatoid arthritis.
    Okamoto H; Kamatani N
    N Engl J Med; 2004 Oct; 351(18):1909; author reply 1909. PubMed ID: 15509828
    [No Abstract]   [Full Text] [Related]  

  • 27. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
    De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
    Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD20 as a target for therapeutic type I and II monoclonal antibodies.
    Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
    Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
    Pers YM; Jorgensen C
    Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
    Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
    Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases.
    Mariette X
    Joint Bone Spine; 2004 Sep; 71(5):357-60. PubMed ID: 15474382
    [No Abstract]   [Full Text] [Related]  

  • 36. [Rituximab treatment of rheumatoid arthritis: new evidence].
    Nasonov EL
    Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
    Korhonen R; Moilanen E
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
    Hainsworth JD
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.